Literature DB >> 9514563

Peripheral antinociceptive effect of an adenosine kinase inhibitor, with augmentation by an adenosine deaminase inhibitor, in the rat formalin test.

Jana Sawynok1, Allison Reid, Anthony Poon.   

Abstract

This study examined the ability of an adenosine kinase inhibitor (5'-amino-5'-deoxyadenosine; NH2dAD), an adenosine deaminase inhibitor (2'-deoxycoformycin), and combinations of these agents to produce a peripheral modulation of the pain signal in the low concentration formalin model. Drugs were administered in combination with 0.5% formalin, or into the contralateral hindpaw to test for systemic effects, and episodes of flinching behaviors determined. Coadministration of NH2dAD 0.1-100 nmol with formalin produced antinociception as revealed by an inhibition of flinching behaviors. This action was peripherally mediated as it was not seen following contralateral administration of the NH2dAD, and was due to accumulation of adenosine and activation of cell surface adenosine receptors as it was blocked by the adenosine receptor antagonist caffeine. Antinociception was intensity-dependent, as it was not seen when higher concentrations of formalin (0.75%, 1.5%) were used. The coadministration of the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine revealed the presence of an inhibitory tone of adenosine when the intrinsic antinociceptive effect of NH2dAD was obscured by the solvent or the stimulus intensity. 2'-Deoxycoformycin 0.1-100 nmol did not produce any intrinsic effect, but 100 nmol coadministered with low concentrations of NH2dAD, which lacked an intrinsic effect, augmented antinociception by NH2dAD. Again, this was a peripheral rather than a systemic response. The combined action of the adenosine kinase and deaminase inhibitors was completely reversed by coadministration of caffeine. Antinociception with NH2dAD is observed at higher concentrations of formalin in second trial experiments. This study demonstrates a peripheral antinociceptive action mediated by endogenous adenosine which accumulates following the peripheral inhibition of adenosine kinase; this action is due to activation of an adenosine A1 receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514563     DOI: 10.1016/S0304-3959(97)00153-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

1.  Effects of dose ranging of adenosine infusion on electrocardiographic findings during and after general anesthesia.

Authors:  Yan-Xia Sun; Ashraf S Habib; Tom Wenger; Irwin Gratz; David Glick; Rishimani Adsumelli; Mary R Creed; Tong J Gan
Journal:  J Anesth       Date:  2012-06-03       Impact factor: 2.078

2.  Sustained Elevated Adenosine via ADORA2B Promotes Chronic Pain through Neuro-immune Interaction.

Authors:  Xia Hu; Morayo G Adebiyi; Jialie Luo; Kaiqi Sun; Thanh-Thuy T Le; Yujin Zhang; Hongyu Wu; Shushan Zhao; Harry Karmouty-Quintana; Hong Liu; Aji Huang; Yuan Edward Wen; Oleg L Zaika; Mykola Mamenko; Oleh M Pochynyuk; Rodney E Kellems; Holger K Eltzschig; Michael R Blackburn; Edgar T Walters; Dong Huang; Hongzhen Hu; Yang Xia
Journal:  Cell Rep       Date:  2016-06-16       Impact factor: 9.423

3.  Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture.

Authors:  Nanna Goldman; Michael Chen; Takumi Fujita; Qiwu Xu; Weiguo Peng; Wei Liu; Tina K Jensen; Yong Pei; Fushun Wang; Xiaoning Han; Jiang-Fan Chen; Jurgen Schnermann; Takahiro Takano; Lane Bekar; Kim Tieu; Maiken Nedergaard
Journal:  Nat Neurosci       Date:  2010-05-30       Impact factor: 24.884

4.  Fructose-1,6-bisphosphate reduces inflammatory pain-like behaviour in mice: role of adenosine acting on A1 receptors.

Authors:  D A Valério; F I Ferreira; T M Cunha; J C Alves-Filho; F O Lima; J R De Oliveira; S H Ferreira; F Q Cunha; R H Queiroz; W A Verri
Journal:  Br J Pharmacol       Date:  2009-07-23       Impact factor: 8.739

5.  PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain.

Authors:  Julie K Hurt; Mark J Zylka
Journal:  Mol Pain       Date:  2012-04-23       Impact factor: 3.395

6.  Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System.

Authors:  Eveline Dischkaln Stolz; Paola Fontoura da Costa; Liciane Fernandes Medeiros; Andressa Souza; Ana Maria Oliveira Battastini; Gilsane Lino von Poser; Carla Bonan; Iraci L S Torres; Stela Maris Kuze Rates
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-21       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.